You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)解熱鎮痛類藥布洛芬顆粒獲通過一致性評價
格隆匯 10-31 18:09

格隆匯10月31日丨石藥集團(01093.HK)宣佈,公司附屬公司石藥集團歐意藥業有限公司開發的"布洛芬顆粒(0.2g)"已獲中國國家藥品監督管理局批准通過仿製藥質量和療效一致性評價。

布洛芬具有鎮痛、解熱和抗炎的作用,可緩解輕至中度疼痛如頭痛、關節痛、偏頭痛、牙痛、肌肉痛、神經痛、痛經,也用於普通感冒或流行性感冒引起的發熱。該產品服用方式為温開水沖服,使兒童患者服藥更加便捷。

布洛芬顆粒為集團解熱鎮痛類藥物的重點產品之一,是國內首家通過一致性評價的同類產品。通過一致性評價,表明該產品質量和療效與原研藥品一致,能為患者提供優質優價的藥用選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account